Physician profile
Paula E Pecen
NPI 1740505528
$8,514.75
in general payments reported to CMS, 2019-2025
19 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2021: $277 · 2022: $3,994 · 2023: $2,824 · 2024: $855 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,254 · Consulting Fee: $1,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,253.60 |
| Consulting Fee | $1,850.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $5,427.31 | 2021-2023 | |
| Genentech USA, INC. | $644.71 | 2021-2024 | Vabysmo, Susvimo |
| Alcon Vision LLC | $640.87 | 2019-2025 | Acrysof Iq Panoptix Uv Iol, Clareon, Hydrus Microstent |
| Regeneron Healthcare Solutions, INC. | $499.63 | 2021-2024 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $346.13 | 2022-2024 | Syfovre |
| Abbvie INC. | $267.58 | 2021-2025 | |
| Astellas Pharma US INC | $213.85 | 2023-2025 | Izervay |
| Amgen INC. | $103.76 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $98.81 | 2022-2023 | Miebo, Visudyne, Xipere |
| Harrow Eye, LLC | $74.64 | 2025 | Iheezo |
| Alimera Sciences, INC. | $63.19 | 2021-2022 | |
| Coherus Oncology, INC. | $29.23 | 2022 | |
| Mallinckrodt Hospital Products INC. | $28.91 | 2021 | |
| Rayner Intraocular Lenses Limited | $24.08 | 2023 | Omidria, Rayone Spheric, Rayone Emv |
| Glaukos Corporation | $19.14 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $19.14 | 2022 | |
| Allergan, INC. | $13.77 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Pecen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.